Print
Email
Print Edition Stories
Health care industry eyes iPad
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
A source close to French drug maker Sanofi-Aventis SA said Monday that Sanofi may be willing to moderately raise its $69-per-share offer to buy Cambridge pharmaceutical company Genzyme Corp. (Nasdaq: GENZ), according to a report by the Dow Jones Newswires.
According to the report, the unidentified source said that Sanofi’s board is split on whether to pursue Genzyme in the wake of Genzyme’s rejection of the $69 offer.
However, the report also noted that Sanofi would be willing in principle to raise its offer of $18.5 billion if Genzyme indicated that it was willing to negotiate.
Last week, Genzyme CEO Henri Termeer said in an interview with Reuters that he would be willing to sell, but not at $69 per share, saying that a deal would only get done when the “strategic value of the company is properly recognized.”
Today, Reuters said that British drug maker GlaxoSmithKline officials have said GSK has no interest in pursuing Genzyme.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
